•Italian businessman Francesco Gaetano Caltagirone expressed concerns that merging Banca Monte dei Paschi di Siena (MPS) and Banco BPM could weaken the historic bank.
•Caltagirone warned that the potential deal could pose a risk to Italian savings.
•A late-stage trial of Imfinzi, combined with a targeted therapy prior to surgery, showed significantly improved survival rates in patients with muscle-invasive bladder cancer.
•METiS TechBio listed on the Hong Kong Stock Exchange under the ticker 7666.HK, becoming the world's first publicly listed AI-powered drug delivery company.
•BIMIZCI filed a definitive proxy statement to nominate three independent directors to the Medallion Financial board for the annual meeting on June 9, 2026.
•BIMIZCI cites deteriorating financial performance, with 1Q26 earnings at their lowest since 2020 and consumer loan charge-offs at 15-year highs.
•BIMIZCI raised governance concerns, including a $4.6 million bonus for the CEO despite a 2025 federal court injunction for securities law violations.
•A New York State judge ruled against Fidelity National Information Services Inc.'s appeal for a reduced corporate tax rate intended for qualified emerging technology companies.
•The court determined that Fidelity National's subsidiaries did not meet eligibility requirements to be assessed as a combined group for the preferential rate.
